Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

62.94
+3.876.55%
Pre-market: 63.310.3700+0.59%06:49 EDT
Volume:2.79M
Turnover:173.13M
Market Cap:5.72B
PE:-11.56
High:63.10
Open:60.72
Low:60.55
Close:59.07
52wk High:71.13
52wk Low:30.04
Shares:90.95M
Float Shares:90.53M
Volume Ratio:1.00
T/O Rate:3.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4437
EPS(LYR):-4.3416
ROE:-25.34%
ROA:-13.05%
PB:3.35
PE(LYR):-14.50

Loading ...

Crispr Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 06

RBC Raises Price Target on CRISPR Therapeutics to $42 From $38, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Aug 05

BUZZ-Crispr Therapeutics falls after weak quarterly results

Reuters
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.86% Pre-Market on Q2 Revenue Miss and Widened Losses

Stock Track
·
Aug 05

Stock Track | CRISPR Therapeutics Plunges 8.46% as Q2 Revenue Misses Estimates, Net Loss Widens

Stock Track
·
Aug 05

CRISPR Therapeutics Ag : RBC Raises Target Price to $42 From $38

THOMSON REUTERS
·
Aug 05

CORRECTION: CRISPR Therapeutics Q2 Adj. EPS $(1.29) Beats $(1.47) Estimate, Sales $892.000K Miss $6.255M Estimate

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 EPS $(2.40) Down From $(1.49) YoY

Benzinga
·
Aug 05

CRISPR Therapeutics Q2 revenue misses estimates, net loss widens

Reuters
·
Aug 05

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Hershey, Wingstop

Reuters
·
Jul 30

BUZZ-U.S. STOCKS ON THE MOVE-Visa, Kraft Heinz, Humana

Reuters
·
Jul 30

Crispr Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

CRISPR Therapeutics Pick of the Week at Smart Insider Following Simeon George's Stock Purchase

MT Newswires Live
·
Jul 22

AI Biotech Stocks Shined. Recursion Soared 10%; Absci Up 7%; Crispr Up 6%; Beam And Ginkgo Up 3%

Tiger Newspress
·
Jul 21

CRISPR Therapeutics AG Director George Simeon Reports Acquisition of Common Shares

Reuters
·
Jul 18

Crispr Therapeutics Price Target Maintained With a $81.00/Share by Needham

Dow Jones
·
Jul 08

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 08

Crispr Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 27

CRISPR Therapeutics Advances Phase 1 Trials for Cardiovascular Disease Programs

MT Newswires Live
·
Jun 26

Crispr Therapeutics Reports Positive Additional Phase 1 Data For Ctx310™ Targeting Angptl3 And Provides Update On In Vivo Cardiovascular Pipeline

Reuters
·
Jun 26